Neoplasms, Plasma Cell: all 2,314 studies
Page 12 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.Active, not recruitingNCT04309981Phase 1/2
- Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer TreatmentCompletedNCT04309942Not applicable
- Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaStatus unknownNCT04309084Phase 1
- The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma PatientsCompletedNCT04303091Not applicable
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT04295018Phase 1
- Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple MyelomaWithdrawnNCT04288765Phase 3
- Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04287855Phase 2
- Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) PatientsStatus unknownNCT04287660Phase 3
- Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT04280328Phase 1
- Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT04277845Phase 2
- Bone Pain in Multiple Myeloma- a Translational StudyStatus unknownNCT04273425
- Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04272151Phase 1/2
- Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.Status unknownNCT04260490
- A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT04244656Phase 1
- Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and BortezomibTerminatedNCT04243109Phase 2
- The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral BloodTerminatedNCT04242121
- Rehabilitation Needs of the Malaysian Haematological Cancer SurvivorsCompletedNCT04236063
- BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaStatus unknownNCT04236011Early Phase 1
- Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple MyelomaWithdrawnNCT04230031Phase 2
- Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction TherapyWithdrawnNCT04223661Phase 2
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Phase 4
- Amplification of Zinc Finger Protein 217 Gene in Multiple MyelomaStatus unknownNCT04212858Not applicable
- A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT04196491Phase 1
- Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple MyelomaStatus unknownNCT04194931Phase 1
- Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMTCompletedNCT04194840Not applicable
- Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple MyelomaStatus unknownNCT04186052Early Phase 1
- A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT04182581Early Phase 1
- A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple MyelomaTerminatedNCT04178902Phase 1
- RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple MyelomaCompletedNCT04176380Phase 2
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT04171843Phase 1
- Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT04163107Phase 1
- Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple MyelomaStatus unknownNCT04162119Phase 2
- BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04156269Early Phase 1
- Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT04155749Phase 1
- VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple MyelomaCompletedNCT04151615
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedNCT04150965Phase 1/2
- Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04150692Phase 2
- A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on PanobinostatCompletedNCT04150289
- Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.Active, not recruitingNCT04144387Not applicable
- Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)TerminatedNCT04142619Phase 1
- Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease ProgressionCompletedNCT04137523
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
- A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)CompletedNCT04135963
- Immune Profiling in Multiple MyelomaCompletedNCT04135079
- Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple MyelomaStatus unknownNCT04122092
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Phase 1
- Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDsTerminatedNCT04106700Phase 2
- Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple MyelomaCompletedNCT04100044Not applicable
- Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled TrialCompletedNCT04099901Phase 2
- Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaTerminatedNCT04083898Phase 1
- Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
- Daratumumab With DCEP for Multiple Myeloma With PlasmacytomaStatus unknownNCT04065308Phase 2
- Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple MyelomaStatus unknownNCT04063189Phase 2
- Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT04036461Phase 1
- A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody TreatmentCompletedNCT04035226
- A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1
- Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 TrialWithdrawnNCT04024384Phase 2
- A Study of MT-0169 in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04017130Phase 1
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable
- Carfilzomib in Combination for the Treatment of RR MMStatus unknownNCT04004338
- Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple MyelomaStatus unknownNCT04003168Phase 1
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positiveStatus unknownNCT03992170Phase 2
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingNCT03989414Phase 1/2
- A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT03984097Phase 1
- Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple MyelomaWithdrawnNCT03983486
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Active, not recruitingNCT03975907Phase 1/2
- Effect of Vitamin C in Autologous Stem Cell TransplantationsCompletedNCT03964688Phase 2
- A Registry Study of Participants With Multiple Myeloma in Latin AmericaCompletedNCT03955900
- Leflunomide in Treating Patients With High-Risk Smoldering Multiple MyelomaWithdrawnNCT03952832Phase 2
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Phase 3
- Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MMActive, not recruitingNCT03948035Phase 3
- BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT03943472Early Phase 1
- Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03942224Phase 2
- B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple MyelomaStatus unknownNCT03931421Phase 2
- Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)Active, not recruitingNCT03915184Phase 1/2
- RDD Versus VDD in Newly Diagnosed Patients With Multiple MyelomaStatus unknownNCT03908138Phase 4
- Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot StudyStatus unknownNCT03903406
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple MyelomaCompletedNCT03870633
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Phase 2
- Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnNCT03856112Phase 1/2
- Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple MyelomaNo longer availableNCT03850704
- PD-L1 Peptide Vaccination in High Risk Smoldering Multiple MyelomaTerminatedNCT03850522Phase 2
- Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple MyelomaCompletedNCT03848676
- Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaWithdrawnNCT03841565Phase 2
- Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaActive, not recruitingNCT03836014Phase 3
- Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03829020Phase 1
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT03815383Phase 1
- Study to Demonstrate Clinical Benefit of Lenalidomide and DexamethasoneActive, not recruitingNCT03809780Phase 2
- 64Cu-LLP2A for Imaging Multiple MyelomaTerminatedNCT03804424Early Phase 1
- Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Status unknownNCT03795597Phase 1/2
- Strength Training in Improving Pain and Quality of Life in Patients With Multiple MyelomaCompletedNCT03793907Not applicable
- Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma PatientsCompletedNCT03792763Phase 2
- Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara ConsolidationStatus unknownNCT03792620Phase 3
- A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
- Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission TomographyCompletedNCT03779815Not applicable
- Lenalidomide Adherence in Older AdultsTerminatedNCT03779555